Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
•
Alcohol-associated Liver Disease
In patients with Met-ALD, how do you approach their treatment plan?
Do you tackle the alcohol first over the metabolic comorbidities?
Related Questions
What role is there for use of ELF in patients with active alcohol use disorder for which Fibroscan is not able to give a reliable assessment of fibrosis due to ongoing active alcohol use?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
How do you utilize the Sustained Alcohol Use Post-Liver Transplant (SALT) score on surveillance for alcohol use for patients after liver transplant?
In what clinical scenario would larsucosterol be considered as therapy in alcohol related hepatitis?
How do you incorporate addiction medicine and counseling into your treatment plan for patients with alcohol associated liver disease?
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?